Stop medication immediately if: Persistent vomiting (more than 3 episodes per day for more than 3 days) Inability to keep down liquids Unintentional weight loss exceeding 2% of body weight per week Signs of dehydration (dark urine, dizziness, reduced urination) Severe abdominal pain Vomiting blood or coffee-ground material Consider dose reduction (rather than stopping) if: Mild to moderate nausea that improves between doses Early satiety but able to maintain nutrition with smaller meals Symptoms that started or worsened with recent dose escalation Weight loss goals are being met and you want to continue treatment Continue current dose with dietary modification if: Mild intermittent nausea Bloating or fullness that resolves within 2-3 hours after meals Symptoms present but not interfering with daily activities No weight loss beyond expected The dose-reduction protocol: If reducing dose rather than stopping: Drop to the previous tolerated dose (if you're at 2 mg semaglutide and symptoms started after escalation from 1 mg, return to 1 mg) Stay at reduced dose for 4 to 6 weeks to assess symptom improvement If symptoms resolve, continue at that dose indefinitely If symptoms persist at reduced dose, discontinue entirely About 40% of patients with mild gastroparesis symptoms can continue treatment at a reduced dose without progression to severe gastroparesis (Acosta et al., Clinical Gastroenterology and Hepatology , 2024)
Strength Level: Standard New
Smaller, more frequent meals tend to feel better than large ones
Peptide therapy involves prescription compounds that require a licensed medical provider, clinical evaluation, and laboratory monitoring
****Einheiten zur Messung der enzymatischen Aktivitt
Often you can, especially if you have a prescription and a receipt that shows its a medical expense
